

BIOGRAPHICAL SKETCH

NAME: **Angel Porgador**

POSITION TITLE: Full Professor

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	Completion Date	FIELD OF STUDY
Hebrew University, Faculty of Medicine, Jerus., Isr.	B.M.Sc	08/1982	Medical Sciences
Hebrew University, Fac. of Life Science, Jerus., Isr.	B.Sc.	08/1984	Computers & Math.
Weizmann Institute of Science, Rehovot, Israel	M.Sc.	09/1988	Life Science
Weizmann Institute of Science, Rehovot, Israel	Ph.D.	09/1993	Life Science
Research Associate, DUMC, Durham, NC, USA	1 st postdoc	08/1995	Tumor Immunology
Visiting Associate, NIAID, NIH, Bethesda, MD, USA	2 nd postdoc	09/1998	Tumor Immunology

A. Personal Statement

My research is focused on innate and adaptive immunity in health and disease and particularly in the areas of tumor immunology and tumor immunotherapy. I strongly believe that for the purpose of fighting cancer successfully, we need to think outside the box and act accordingly in our research.

B. Positions

Positions and Employment:

1998-2000 Lecturer, Dept. of Microbiology & Immunology, Faculty of Health sciences, BGU

2000-2005 Senior Lecturer, Dept. of Microbiology & Immunology, Faculty of Health sciences, BGU

2005-2010 Associate Professor, Dept. of Microbiology & Immunology, Faculty of Health sciences, BGU

2011-Present Full Professor, Dept. of Microbiology & Immunology, Faculty of Health sciences, BGU

2011-2014 Deputy Dean for Research & Development, Faculty of Health Sciences, BGU

2014- Present Deputy Vice President and Dean for Research & Development, BGU

Member in management committees of scientific societies

2006- 2008 Israel Immunological Society (IIS)

2008- 2009 Israel Vaccine Research initiative
2010-present Member founder of WIN consortium for Pharma and Academy
collaboration
2010-2012 Vice president, Israel Immunological Society (IIS)
2012-2014 President, Israel Immunological Society (IIS)
2015-2018 Society Executive Secretary, Israeli Society for Cancer Research
2017-present President, Federation of the Israel Societies for Experimental Biology
(FISEB)
2018-present President, Israeli Society for Cancer Research (ISCR)

Commercialization

- 2018 – PiNK Biopharma : Innate Immune Checkpoint (FuturX)
- Commercialization efforts: CARTIV, TRAMMICS, LENTGH, TEVA

- > 120 publications
- > 11,000 citations
- > 10 patent families
- > \$5m in research funds
- > 30 graduate students and post doc graduated